Ivermectin – Newest Vaccine Warrior

Just when we thought we are on the losing side of the COVID-19 pandemic, a snowball effect was set in motion when the world first got wind of the what the Internet has dubbed the COVID-19 wonder drug – Ivermectin.

While we still await a recognized effective treatment or vaccines for the pandemic, Ivermectin – a drug with a wide bioactivity range that has been in use for more than 30 years primarily in the treatment of parasitic infections in humans, is now being considered as a potential target drug for the virus and is currently undergoing extensive research in clinical trials.

The snowball first started to gain traction back in December 2020, when a team of highly published ICU critical care physicians and scholars conducted a comprehensive analysis of scientific data curated from centers around the world that supports the use of the oral medication as a solution for the pandemic.

The team held a webinar in which they called for immediate action from several worldwide national health authorities to conduct a prompt review of their findings with the goal of ultimately greenlighting Ivermectin as a solution in the fight against the disease.

One of the team members has even testified at a U.S. Senate hearing on the early treatments of COVID-19 where he went on record to say that “I am here to report that our group, led by Professor Paul E. Marik, has developed a highly effective protocol for preventing and early treatment of COVID-19.”

The group maintain that the chemical in question has a potent combination of anti-viral and anti-inflammatory assets that render it useful preventively and can also be used for treating the virus at its early and late stages.

Further adding to the appeal of Ivermectin is that the drug is off-patent and extremely cheap, so cheap its already popping up on black markets around the world – where even there its being sold at relatively acceptable prices.

With the snowball effect reaching full momentum, Oxford University has announced that their researchers have gotten the go-ahead and are planning a large-scale trial of the inexpensive drug that could aid in dramatically reducing virus deaths globally.

When it comes to the actual reality of all the ambiguity surrounding the Ivermectin remedy, the data is hopeful yet incomplete, no large-scale randomized control trials have been conducted yet that prove its efficacy, so bets are on Oxford University.